Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma

• Main Authors: Hsin-Yu Kuo (Author), Meng-Zhi Han (Author), Chih-Hsiang Liao (Author), Yih-Jyh Lin (Author), Chung-Teng Wang (Author), Shang-Hung Chen (Author), Ting-Tsung Chang (Author), Po-Jun Chen (Author), Sheng-Hsiang Lin (Author), Chiung-Yu Chen (Author), Chiao-Hsiung Chuang (Author), I-Chin Wu (Author), Juei-Seng Wu (Author), Tzu-Chun Hong (Author), Ming-Tsung Hsieh (Author), Yang-Cheng Lee (Author), Hung-Tsung Wu (Author), Hong-Ming Tsai (Author)
• Format: Book
• Published: MDPI AG, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose: Immune checkpoint inhibitors are effective therapies for advanced hepatocellular carcinoma (HCC); however, comparisons of the clinical efficacy and safety profile for these drugs are still scarce. Thus, the aims of this study were to investigate the differences in efficacy and safety betwee...